Stocks to Watch: Palantir, Coinbase, Nike
The military software firm Palantir (PLTR) is the key stock to watch today. The stock is on a year-long uptrend. After a notable dip in February and again in April, the stock exhibited unusual selling on June 27. Palantir stock dropped by 9.37% that day.Investors likely booked profits on PLTR stock after it reached an all-time high on June 25. Risks are high that $147.67 is the peak. The stock gained 432.33% in the last year and 72.87% YTD.Coinbase (COIN) dropped back to the $363 range after touching $382.00 late last week. At a 66.2 times price-to-earnings ratio, the monthly gain of 38.99% may not hold. The Senate passed a bill that helps stablecoins. That would give Coinbase’s platform a boost. Still, competition for deposits will grow as firms market their services aggressively.Nike (NKE) gained 20.49% last week after posting weak earnings and revenue. The company is expecting tariffs would increase its costs by around $1 billion. Still, Nike CFO Matthew Friend said that China’s manufacturing capacity and capability are important to its global sourcing base.NKE stock closed at a forward P/E of 41.49 times. However, sales in China fell by 13% Y/Y in fiscal 2025. Investors liked its plans to relocate its supply chain outside of China. This will increase its costs, pressuring its operating margins.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


